INYECCIÓN INTRAVÍTREA DE BEVACIZUMAB PARA EDEMA MACULAR QUÍSTICO PSEUDOFÁQUICO RESISTENTE A ESTEROIDES INTRAVITREAL INJECTION OF BEVACIZUMAB FOR PSEUDOPHAKIC CYSTOID MACULAR EDEMA RESISTANT TO STEROIDS

Clinical case: A 71-year-old man presented with pseudophakic cystoid macular edema (PCME) and a visual acuity (VA) of 0.1. He had been treated with 2 intra-vitreal injections of triamcinolone acetonide (4 mg) 16 months previously. One week after the intra-vitreal injection of bevacizumab (1.25 mg), VA improved to 0.33, and the OCT demonstrated decreased macular thickness. Two months after the injection, no ocular complications were observed, VA was 0.5 and the OCT showed a significant reduction in the retinal thickness. Conclusion: Intra-vitreal injection of bevacizumab may be an additional tool for the treatment of therapy-resistant PCME (Arch Soc Esp Oftalmol 2007; 82: 447-450).